Metronomic Chemotherapy with the COMBAT Regimen in Advanced
Pediatric Malignancies: A Multicenter Experience

J 2012

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

ZAPLETALOVÁ, Danica; Nicolas ANDRE; Ladislav DEAK; Michal KÝR; Viera BAJČIOVÁ et. al.

Základní údaje

Originální název

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

Autoři

Vydání

Oncology, Basel, S. Karger AG, 2012, 0030-2414

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.165

Kód RIV

RIV/00216224:14110/12:00060447

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1159/000336483

UT WoS

000303655300001

Klíčová slova anglicky

Children; Solid tumor; Tumor angiogenesis; Metronomic chemotherapy; Relapsed pediatric solid tumor

Příznaky

Mezinárodní význam

Změněno: 22. 4. 2013 18:36, Soňa Böhmová

Anotace

V originále

The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade >= 2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

MUNI/A/0950/2010, interní kód MU

Název: Metronomická léčba v dětské onkologii

Investor: Masarykova univerzita, Metronomická léčba v dětské onkologii, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

ZAPLETALOVÁ, Danica; Nicolas ANDRE; Ladislav DEAK; Michal KÝR; Viera BAJČIOVÁ; Peter MÚDRY; Lenka DUBSKÁ; Regina DEMLOVÁ; Zdeněk PAVELKA; Karel ZITTERBART; Jarmila SKOTÁKOVÁ; Karel HUŠEK; Alexandra MARTINČEKOVÁ; Pavel MAZÁNEK; Tomáš KEPÁK; Michael DOUBEK; Lucia KÚTNIKOVÁ; Dalibor VALÍK a Jaroslav ŠTĚRBA. Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience. Oncology. Basel: S. Karger AG, 2012, roč. 82, č. 5, s. 249-260. ISSN 0030-2414. Dostupné z: https://doi.org/10.1159/000336483.

@article{987447,
   author = {Zapletalová, Danica and Andre, Nicolas and Deak, Ladislav and Kýr, Michal and Bajčiová, Viera and Múdry, Peter and Dubská, Lenka and Demlová, Regina and Pavelka, Zdeněk and Zitterbart, Karel and Skotáková, Jarmila and Hušek, Karel and Martinčeková, Alexandra and Mazánek, Pavel and Kepák, Tomáš and Doubek, Michael and Kútniková, Lucia and Valík, Dalibor and Štěrba, Jaroslav},
   article_location = {Basel},
   article_number = {5},
   doi = {https://doi.org/10.1159/000336483},
   keywords = {Children; Solid tumor; Tumor angiogenesis; Metronomic chemotherapy; Relapsed pediatric solid tumor},
   language = {eng},
   issn = {0030-2414},
   journal = {Oncology},
   title = {Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience},
   volume = {82},
   year = {2012}
}

TY  - JOUR
ID  - 987447
AU  - Zapletalová, Danica - Andre, Nicolas - Deak, Ladislav - Kýr, Michal - Bajčiová, Viera - Múdry, Peter - Dubská, Lenka - Demlová, Regina - Pavelka, Zdeněk - Zitterbart, Karel - Skotáková, Jarmila - Hušek, Karel - Martinčeková, Alexandra - Mazánek, Pavel - Kepák, Tomáš - Doubek, Michael - Kútniková, Lucia - Valík, Dalibor - Štěrba, Jaroslav
PY  - 2012
TI  - Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience
JF  - Oncology
VL  - 82
IS  - 5
SP  - 249-260
EP  - 249-260
PB  - S. Karger AG
SN  - 00302414
KW  - Children
KW  - Solid tumor
KW  - Tumor angiogenesis
KW  - Metronomic chemotherapy
KW  - Relapsed pediatric solid tumor
N2  - The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade >= 2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.
ER  -

ZAPLETALOVÁ, Danica; Nicolas ANDRE; Ladislav DEAK; Michal KÝR; Viera BAJČIOVÁ; Peter MÚDRY; Lenka DUBSKÁ; Regina DEMLOVÁ; Zdeněk PAVELKA; Karel ZITTERBART; Jarmila SKOTÁKOVÁ; Karel HUŠEK; Alexandra MARTINČEKOVÁ; Pavel MAZÁNEK; Tomáš KEPÁK; Michael DOUBEK; Lucia KÚTNIKOVÁ; Dalibor VALÍK a Jaroslav ŠTĚRBA. Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience. \textit{Oncology}. Basel: S. Karger AG, 2012, roč.~82, č.~5, s.~249-260. ISSN~0030-2414. Dostupné z: https://doi.org/10.1159/000336483.

Přehled o publikaci